Tesamorelin

What is Tesamorelin?

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). It is a modified version of the natural GHRH peptide, stabilized with an added chemical group so it resists breakdown and remains active longer in the body. By acting on the pituitary gland, it prompts the body to release its own growth hormone in a natural, pulsatile pattern.

Unlike injected growth hormone itself, tesamorelin works upstream — it stimulates the pituitary rather than replacing the hormone directly, which preserves the body's own feedback control. It is best known under the brand name Egrifta.

Tesamorelin is FDA-approved for one specific indication: the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Any use outside that indication — for general visceral-fat reduction in people without HIV — is off-label and, when compounded, is dispensed only through a licensed pharmacy under physician supervision.

How Tesamorelin works

Tesamorelin binds to GHRH receptors on the anterior pituitary, stimulating the synthesis and pulsatile release of growth hormone (GH). The released GH in turn raises circulating insulin-like growth factor 1 (IGF-1), the downstream mediator of most of GH's metabolic effects.

Elevated GH activity preferentially mobilizes visceral adipose tissue — the metabolically active fat packed around the abdominal organs — by promoting lipolysis. This is why tesamorelin's signature effect is a reduction in visceral fat specifically, rather than broad weight loss, and why body weight often changes little even as waistline and visceral-fat measures fall.

Because it preserves the natural GH pulse and the body's negative-feedback loops, tesamorelin is designed to avoid the sustained, supraphysiologic GH levels associated with direct GH administration, though IGF-1 still requires monitoring.

What Tesamorelin is used for

What the evidence shows

Tesamorelin is unusual among peptides in this space for having genuine, high-quality human evidence. In a pivotal double-blind, randomized, placebo-controlled trial published in the New England Journal of Medicine, patients with HIV-associated abdominal fat accumulation who received tesamorelin had a significant reduction in visceral adipose tissue versus placebo, without a comparable loss of subcutaneous fat [1].

Subsequent trials and pooled analyses confirmed the visceral-fat effect and characterized the accompanying rise in IGF-1, as well as the observation that visceral fat tends to return after the drug is stopped — supporting the idea that continued treatment is needed to maintain the effect [2][3]. These data underpin the FDA approval of Egrifta.

The important caveat is scope: the randomized evidence was generated in the HIV-lipodystrophy population. Extending tesamorelin to visceral-fat reduction in people without HIV is a reasonable mechanistic extrapolation, but it is off-label, and we say so plainly. The approved indication is well-supported; broader use rests on that mechanism plus clinical judgment.

Dosing & administration context

In its approved form, tesamorelin is given as a once-daily subcutaneous injection, with dosing established by the manufacturer's labeling. Effects on visceral fat typically develop over months rather than weeks, and treatment is generally continued because the benefit reverses after stopping.

The specific dose, injection technique, and duration are set by the prescribing physician based on your indication, IGF-1 and glucose response, and tolerance. We present this as clinical context, not a self-dosing guide.

Tesamorelin obtained outside a licensed pharmacy — research-only vials or gray-market powder — carries no assurance of identity, purity, sterility, or correct concentration, and we do not use it. Reconstitution and cold-chain handling matter for this peptide.

Tesamorelin (Egrifta) is FDA-approved only for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Use for visceral-fat reduction in other patients is off-label; compounded tesamorelin is prescribed for physician-supervised use through licensed pharmacies. This page is clinical context, not a dosing guide or a substitute for medical advice.

Safety & side effects

Because tesamorelin raises GH and IGF-1, its most clinically relevant effects relate to glucose metabolism. It can worsen insulin sensitivity and raise blood sugar, so it is used cautiously in people with diabetes or prediabetes, and glucose is monitored throughout treatment.

Injection-site reactions are the most common complaint. Fluid-retention effects — joint aches, swelling, or carpal-tunnel-type symptoms — can occur, as with other agents that raise GH activity, and generally track with IGF-1 levels.

We screen carefully before prescribing and monitor IGF-1 and metabolic markers on a schedule. Source control is central: an FDA-approved product or a preparation from a licensed 503A/503B compounding pharmacy is a fundamentally different risk profile than an unregulated vial.

How Strong Health prescribes Tesamorelin

At Strong Health, tesamorelin is prescribed only after a physician evaluation — in person at our Brickell (Miami) clinic or via telehealth — including a review of your metabolic history and baseline labs. We check IGF-1 and glucose before starting and re-check them on a defined schedule.

We dispense only through FDA-approved manufacturers or licensed 503A and 503B compounding pharmacies under physician orders; we never use research-only or gray-market product. Where a patient's goal is off-label visceral-fat reduction, we are explicit that the FDA approval is specific to HIV-associated lipodystrophy.

Tesamorelin is treated as one part of a metabolic plan, not a standalone fix. Your physician sets the protocol, reviews IGF-1 and glucose at intervals, and adjusts or stops treatment based on your labs and response.

Available in person at our Miami (Brickell) clinic and via telehealth across our service areas.

Frequently asked questions